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Abstract
Background: Testicular germ cell tumors (TGCT) are the most common cancer entities in young men with increasing
incidence observed in the last decades. For therapeutic management it is important, that TGCT are divided into several
histological subtypes. MED15 is part of the multiprotein Mediator complex which presents an integrative hub for
transcriptional regulation and is known to be deregulated in several malignancies, such as prostate cancer and
bladder cancer role, whereas the role of the Mediator complex in TGCT has not been investigated so far. Aim of
the study was to investigate the implication of MED15 in TGCT development and its stratification into histological
subtypes.
Methods: Immunohistochemical staining (IHC) against Mediator complex subunit MED15 was conducted on a
TGCT cohort containing tumor-free testis (n = 35), intratubular germ cell neoplasia unclassified (IGCNU, n = 14),
seminomas (SEM, n = 107) and non-seminomatous germ cell tumors (NSGCT, n = 42), further subdivided into
embryonic carcinomas (EC, n = 30), yolk sac tumors (YST, n = 5), chorionic carcinomas (CC, n = 5) and teratomas
(TER, n = 2). Quantification of MED15 protein expression was performed through IHC followed by semi-quantitative
image analysis using the Definiens software.
Results: In tumor-free seminiferous tubules, MED15 protein expression was absent or only low expressed in
spermatogonia. Interestingly, the precursor lesions IGCNU exhibited heterogeneous but partly very strong MED15
expression. SEM weakly express the Mediator complex subunit MED15, whereas NSGCT and especially EC show
significantly enhanced expression compared to tumor-free testis.
Conclusions: In conclusion, MED15 is differentially expressed in tumor-free testis and TGCT. While MED15 is absent or
low in tumor-free testis and SEM, NSGCT highly express MED15, hinting at the diagnostic potential of this marker to
distinguish between SEM and NSGCT. Further, the precursor lesion IGCNU showed increased nuclear MED15 expression
in the preinvasive precursor cells, which may provide diagnostic value to distinguish between benign and pre-malignant
testicular specimen, and may indicate a role for MED15 in carcinogenesis in TGCT.
Background
In young men at the age of 15 to 40 years, testicular germ
cell tumors (TGCT) are the most frequent malignant tu-
mors [1]. Interestingly, an increasing incidence in TGCT
has been observed over the last 40 years [2]. TGCTare his-
tologically and clinically grouped into seminomas (SEM)
and non-seminomatous germ cell tumors (NSGCT), which
are further subdivided into embryonic carcinomas (EC),
yolk sac tumors (YST), chorionic carcinomas (CC), and
teratomas (TER) [3]. Generally, NSGCT have a more
aggressive and undifferentiated phenotype than SEM
and tend to be metastatic [4]. Therefore, the histological
distinction between these tumor subentities plays an im-
portant role for the therapeutic management and new bio-
markers are needed for higher sensitivity in diagnostics.
MED15 is part of the multiprotein Mediator complex
(MED) and serves as a hub for important signaling path-
ways, transcriptional co-activators and co-repressors form-
ing a bridge between the RNA polymerase II (Pol II) and
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transcriptional factors [5, 6]. The Mediator complex has
frequently been described to be differentially expressed or
mutated in diverse tumor entities [7]. Interestingly,
MED15 belongs to the tail module of the Mediator com-
plex, which is known to receive and integrate information
from diverse signaling pathways such as the transforming
growth factor-β (TGF-β) and sterol regulatory element-
binding protein (SREBP) pathways [8–10]. While some
cancer entities were shown to be strongly associated with
MED deregulation, knowledge about the Mediator com-
plex expression profile in TGCT has been lacking so far.
We therefore evaluated the MED15 expression in tumor-
free testis and TGCT subentities by immunohistochemical
staining (IHC) on a large tissue microarray (TMA) cohort
in order to evaluate a possible diagnostic and therapeutic
value for MED15 in TGCT.
Methods
Tissue samples of primary TGCT
In this study tissue microarrays (TMA) containing speci-
mens of testes were used to examine the MED15 protein
expression by immunohistochemical analysis. The TGCT
cohorts, kindly provided by the Institute for Pathology
Göttingen and the Urology Department of the University
Hospital Bonn, include the following tissue samples: 35
tumor-free testes, 14 intratubular germ cell neoplasia
unclassified (IGCNU), 107 seminomas (SEM) and 42
non-seminomatous germ cell tumors (NSGCT), further
subdivided into embryonic carcinomas (EC, n = 30), yolk
sac tumors (YST, n = 5), chorionic carcinomas (CC, n = 5)
and teratomas (TER, n = 2). Ethical approval for using hu-
man material in the present study was obtained from
the ethics committee of the University Medical Centre
Göttingen and Bonn.
The TMA was constructed as described previously [11].
Briefly, formalin-fixed paraffin-embedded tissues were cut
into 4 μm thick sections and were mounted on slides. After
staining with haematoxylin and eosin (H&E), areas of nor-
mal tissue and primary tumor were determined and circled
by a pathologist. Representative cores of the circled re-
gions, measuring 0.6 mm in diameter from each formalin-
fixed paraffin-embedded (FFPE) benign tissue and primary
tumor, were assembled into tissue microarray blocks
(recipient blocks) using a semiautomatic tissue arrayer
(Beecher Instruments, Sun Prairie, WI, USA). H&E TMA
sections were assessed again to confirm the histology of
the selected regions.
Immunohistochemical analysis (IHC)
Immunohistochemical staining was conducted using the
Ventana Benchmark automated staining system (Ventana
Medical System, Tuscon, AZ, USA). In brief, slides were in-
cubated at room temperature with the primary anti-
body according to the manufacturer (dilutions, clones,
manufacturer): anti-MED15 rabbit polyclonal (1:100,
11566-1-AP, Proteintech, Chicago, IL, USA). Antibody
dilution was conducted using a Ventana diluent. Signal de-
tection was done using the ultraView Universal DAB de-
tection kit (Ventana Medical System, Tuscon, AZ, USA).
Finally, slides were counterstained with haematoxylin and
bluing reagent, dehydrated, and mounted. IHC stainings
were validated independently by two pathologists (F.B.,
S.P). Only cases with at least one assessable core were in-
cluded in this analysis. Tumor samples with a lack of tis-
sue or absence of carcinoma were excluded.
Quantification of protein expression
Quantification of MED15 protein expression was per-
formed using the semi-quantitative image analysis pro-
gram Definiens (Definiens Inc., Munich, Germany). Hereby,
the pathologist chose manually the tumor area within the
testicular specimens. Afterwards, the program analyzed the
selected regions of interest with respect to overall protein
expression using the average staining intensity (mean
brown chromogen intensity) and the number of posi-
tively stained cells determined through an intensity thresh-
old in relation to all analyzed cells in a sample (positive
index). The statistical evaluation of the expression intensity
was performed using the two-sided Student’s t-test in SPSS
Statistics 22 (SPSS Inc., Chicago, IL, USA).
Results
MED15 expression in tumor-free testes, precursor lesions,
seminomas and non-seminomatous germ cell tumors
In tumor-free testes the MED15 protein expression was
absent or low. Interestingly, pre-eminently the pluripotent
spermatogonia exhibit moderate MED15 expression in the
tumor-free testis (Fig. 1a). Intratubular germ cell neoplasia
unclassified (IGCNU) showed increased nuclear MED15
expression in the preinvasive precursor cells and an in-
creased positive index (Fig. 1b).
In SEM, MED15 expression was predominantly low or
completely absent (Fig. 1c). In contrast, non-seminomatous
germ cell tumors (NSGCT) exhibited a significantly higher
MED15 expression and positivity index as compared to
tumor-free testes and SEM. Especially, the staining pattern
in EC showed strong homogeneous expression of MED15
in the nuclei and cytoplasm (Fig. 2a). Likewise, samples of
NSGCT, YST (Fig. 2b) and CC (Fig. 2c) exhibited elevated
nuclear and cytoplasmic MED15 expression as compared
to tumor-free testes and SEM. TER were found with high
diversity in MED15 expression in line with their histologic
heterogeneity (data not shown). In conclusion, the NSGCT
significantly overexpress MED15 as compared to tumor-
free testes and SEM (p < 0.001). Further, IGCNU as a pre-
malignant precursor lesion of the testes showed enhanced
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MED15 protein expression as compared to benign tis-
sue (p < 0.01) (Fig. 3a). Interestingly, NSGCT showed
an elevated MED15 positive index indicating a homoge-
neous expression in the tumor, whereas tumor-free testes
and SEM showed significantly lower positive indexes
(p < 0.001) (Fig. 3b).
Discussion
In this study, we found MED15 nuclear and cytoplasmic
expression to be significantly higher in NSGCT as com-
pared to tumor-free testes and SEM. Further, the precur-
sor lesion intratubular germ cell neoplasia unclassified
(IGCNU) exhibited increased nuclear MED15 expression
Fig. 1 Representative IHC images for MED15 expression from tissue of tumor-free testis (a), intratubular germ cell neoplasia unclassified (IGCNU)
(b) and seminoma (SEM) (c). 10× (upper panel) and 40× (lower panel) objective magnification
Fig. 2 Representative IHC images for MED15 expression from tissue of the different non-seminomatous germ cell tumors (NSGCT) embryonic carcinoma
(EC) (a), yolk sac tumor (YST) (b) and chorionic carcinoma (CC) (c). 10× (upper panel) and 40× (lower panel) objective magnification
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in the preinvasive precursor cells as compared to benign
tissue which may be a hint for MED15 overexpression as
a clonal event in TGCT development. Interestingly,
MED15 was found to be homogeneously expressed in
NSGCT (positive index >0.8) pointing at a possible
role for MED15 in selection of precursor tumor cells
during carcinogenesis. MED15 is part of the Mediator com-
plex, which is an evolutionarily conserved multi-protein as-
sembly. It plays a pivotal role in transcriptional regulation
forming a bridge between transcriptional factors and the
RNA polymerase II (Pol II) [5]. The complex can be subdi-
vided into four distinct submodules termed the head, mid-
dle, tail and kinase. While the head, middle and tail module
form a stable core complex, the kinase module associates
reversibly with the core complex thereby influencing the
activity of the whole complex [6]. Generally, the head and
middle modules interact directly with Pol II, the main part
of the core associated basal transcription machinery,
whereas the tail and kinase modules serve as major loci
for signal transduction and diverse signaling pathways [5].
Genomic alteration as well as altered expression of dis-
tinct Mediator complex subunits (MED) can cause dys-
functions and dysregulations of cell signaling and may
contribute to malignant properties through directly medi-
ating target gene transcription [7]. Diverse MED subunits
have been associated with tumor development, progres-
sion and the emergence of chemoresistance, which re-
mains one of the key problems in oncologic therapy.
Fig. 3 a Nuclear MED15 protein expression profile of the total testicular germ cell tumor (TCGT) cohort. b Positive index of the MED15
immunhistochemical staining on the TGCT cohort. (n.s. = not significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001)
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Even though modern therapeutical options for TGCT
such as radical orchiectomy and chemotherapy achieve
high cure rates, a small group of patients nevertheless
experiences late relapse, metastatic spread or chemore-
sistance which leads to poor prognosis and underlines
the importance for unraveling the responsible mecha-
nisms [12].
MED15 is part of the tail module and is known to serve
as a hub for signaling pathways including transforming
growth factor-β (TGF-β) signaling as well as the signaling
of sterol regulatory element-binding proteins (SREBP)
[8, 9]. The TGF-β signaling pathway is a double-edged
sword, with either tumor suppressive or oncogenic fea-
tures depending on the stage of disease [10]. For example,
in castration-resistant prostate cancer, MED15 is frequently
overexpressed and correlates with pSmad3 expression, a
downstream target indicating activation of the TGF-β sig-
naling cascade [13]. MED15 was further described to retain
TAZ (transcriptional co-activator with PDZ-binding motif)
in the nucleus, which engages in shuttling Smad complexes
and dominantly regulates Smad nuclear accumulation,
thereby positively regulating TGF-β target gene expres-
sion. In human embryonic stem cells MED15 is required
for stem cell maintenance and pluripotency through direct
interaction with TAZ leading to Smad nuclear accumula-
tion and target gene transcription, whereas loss of TAZ
leads to inhibition of TGF-β signaling and differentiation.
This is in line with the results presented in the current
study, which shows a significantly enhanced MED15
expression in pluripotent EC [14]. Interestingly, treat-
ment of the seminoma cell line TCam-2 with recom-
binant TGF-β1 induces differentiation into a cell type
resembling mixed non-seminoma [15] suggesting MED15
as an integrative hub for this differentiation process.
In addition, activated TGF-β signaling leads to induction
of epithelial-to-mesenchymal transition, which is known to
be implicated in tumor progression, metastatic spread and
increased chemoresistance [16, 17, 10]. Thus, positive regu-
lation of TGF-β signaling might indicate a role of MED15
in the emerging of an aggressive phenotype. Therefore, en-
hanced MED15 protein expression found in TCGT could
be a hint for non-responsive and invasive tumors and re-
quires further investigation. Previously, the SREBP target
gene fatty acid synthase (FASN), which is a key enzyme re-
sponsible for the endogenous synthesis of fatty acids and
described to be upregulated in different tumors, was de-
tected to be differentially expressed in TCGT. Especially,
EC frequently overexpress FASN, whereas SEM and
tumor-free testes express FASN rarely [18]. Considering the
strong overexpression of MED15 in TGCT and EC as pre-
sented here, the involvement of the MED15-SREBP-FASN
axis in tumor formation and differentiation should be in-
vestigated in detail with the aim to potentially develop diag-
nostic biomarker and identify novel therapeutic targets.
Conclusions
In conclusion, the differential protein expression of Medi-
ator complex subunit MED15 in TGCT may provide valu-
able as a diagnostic marker and may assist the selection of
therapeutic intervention. MED15 is expressed significantly
higher in precursor lesion IGCNU as compared to tumor-
free testes and may thus prove useful as a diagnostic feature
to distinguish between benign and pre-malignant tissue.
Furthermore, MED15 may play a role in the differentiation
process between seminomas and non-seminomas.
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